Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

<p>HRR gene mutations found in WGS/WES or clinical BRCA1/2 mutational testing.</p>

Збережено в:

Бібліографічні деталі
Автор:	Sanna Pikkusaari (15055802) (author)
Інші автори:	Manuela Tumiati (15011915) (author), Anni Virtanen (15055805) (author), Jaana Oikkonen (14948281) (author), Yilin Li (15055808) (author), Fernando Perez-Villatoro (15055811) (author), Taru Muranen (15055814) (author), Matilda Salko (15055817) (author), Kaisa Huhtinen (15055820) (author), Anna Kanerva (15055823) (author), Heidi Koskela (15055826) (author), Johanna Tapper (15055829) (author), Riitta Koivisto-Korander (15055832) (author), Titta Joutsiniemi (15055835) (author), Ulla-Maija Haltia (15055838) (author), Heini Lassus (15055841) (author), Sampsa Hautaniemi (14948308) (author), Anniina Färkkilä (14948278) (author), Johanna Hynninen (14932815) (author), Sakari Hietanen (14932818) (author), Olli Carpén (14932812) (author), Liisa Kauppi (15055844) (author)
Опубліковано:	2025
Предмети:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Prognostic biomarkers Chemotherapy DNA Damage and Repair Drug Resistance Clinical drug resistance Gynecological Cancers Ovarian cancer Precision Medicine
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
за авторством: Sanna Pikkusaari (15055802)
Опубліковано: (2025)

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
за авторством: Stephanie L. Wethington (16354020)
Опубліковано: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
за авторством: Arun Kanakkanthara (14937731)
Опубліковано: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
за авторством: Arun Kanakkanthara (14937731)
Опубліковано: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
за авторством: Jiachun Su (16990970)
Опубліковано: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
за авторством: Xiaohong Hong (22681698)
Опубліковано: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
за авторством: Kavya Ramkumar (16474203)
Опубліковано: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
за авторством: Alex C.H. Liu (14961921)
Опубліковано: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
за авторством: Alex C.H. Liu (14961921)
Опубліковано: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
за авторством: Alex C.H. Liu (14961921)
Опубліковано: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
за авторством: Alex C.H. Liu (14961921)
Опубліковано: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
за авторством: Alex C.H. Liu (14961921)
Опубліковано: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
за авторством: Alex C.H. Liu (14961921)
Опубліковано: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
за авторством: Phyllis S.Y. Chong (17141520)
Опубліковано: (2025)

Supplementary Table S2 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
за авторством: Phyllis S.Y. Chong (17141520)
Опубліковано: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
за авторством: Milana A. Bergamino (15038015)
Опубліковано: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
за авторством: Milana A. Bergamino (15038015)
Опубліковано: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
за авторством: Milana A. Bergamino (15038015)
Опубліковано: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
за авторством: Milana A. Bergamino (15038015)
Опубліковано: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
за авторством: Milana A. Bergamino (15038015)
Опубліковано: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
за авторством: Milana A. Bergamino (15038015)
Опубліковано: (2025)

Movie S1 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
за авторством: Jill Gallaher (16799594)
Опубліковано: (2025)

Movie S2 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
за авторством: Jill Gallaher (16799594)
Опубліковано: (2025)

Movie S3 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
за авторством: Jill Gallaher (16799594)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qu50atjsnebr8uf2m4aus0hnc6